# Precision Epigenomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precision-epigenomics

- Industry: Medical Devices & Equipment
- Headquarters: Tucson, US
- Website: www.precision-epigenomics.com/
- Total disclosed funding: $1.1M
- Latest round: Series A (Mar 18, 2024)
- Investors on record: 2

## About

Based in Arizona, US, and founded in 2021 by co-founder and CEO Mark A. Nelson, PhD, Precision Epigenomics Inc., formerly known as DesertDX, LLC, operates as a provider of the EPISEEK liquid biopsy test to adults, particularly those aged 45 and older, for early cancer detection. In March 2024, Precision Epigenomics Inc. raised USD 1.7 million in Series A funding led by Shaffer Capital, LLC, with participation from DVRGNT Ventures.

The company provides early cancer detection services, including the EPISEEK test, which identifies specific cancer-related DNA methylation patterns from a simple blood draw. The test can detect up to 20 types of cancer, including in early stages. Additionally, the firm also provides comprehensive test result interpretation and support services for healthcare providers.

## Funding rounds

- Series A, Mar 18, 2024, $1.1M — DVRGNT Ventures, Shaffer Capital, LLC

## Investors

- DVRGNT Ventures (https://capitalatlas.ai/funds/dvrgnt-ventures) — Series A
- Shaffer Capital, LLC — Series A